September 13, 2016

Salk welcomes new trustee Eric S. Sagerman

索尔克新闻


Salk welcomes new trustee Eric S. Sagerman

Eric S. Sagerman
Eric S. Sagerman

LA JOLLA—The Salk Institute Board of Trustees welcomes its newest trustee, Eric S. Sagerman. Chaired by Irwin M. Jacobs, the 33-member Salk board helps drives the strategic direction of the Institute founded by polio vaccine pioneer Jonas Salk in 1960.

A strategic advisor to companies across multiple industries around the globe, Sagerman brings broad financial, technology and health care experience to his new role at Salk. Most recently, from 2009 to 2011, he was CEO and president of the medical records company Universata, which he restructured and orchestrated its successful sale. From 1999 to 2008, Sagerman was a managing director and Head of Strategy and Strategic Marketing for Allianz Global Investors—Munich, a successor firm to Nicholas Applegate Capital Management, where he was a managing director and member of the executive committee.

In his 16 years with American Express, Sagerman served in a number of marketing and business management posts, both domestically and internationally. As senior vice president, he was involved in many growth and restructuring initiatives, including launching the Global Network Services business, the Corporate Card business and the Centurion “Black” Card.

Sagerman currently serves on the board of Teach for America, San Diego, and is a member of the Salk Institute Investment Committee. He is a former board member of RAS Asset Management in Milan, Italy.

Sagerman earned a BA in economics from Tufts University and an MBA from the Amos Tuck School, Dartmouth College. He and his wife, Jane, live in La Jolla, California.

更多信息

宣传办公室
电话:(858) 453-4100
press@salk.edu

萨尔克生物学研究所

萨尔克研究所是一个独立的非营利性研究机构,由首个安全有效的脊髓灰质炎疫苗的研发者乔纳斯·索尔克于1960年创立。该研究所的使命是推动以合作、敢于冒险为特点的基础性研究,以应对癌症、阿尔茨海默病和农业脆弱性等社会最紧迫的挑战。这项基础科学支撑着所有的转化研究,产生有助于全球新药和创新的见解。.